antipyrine has been researched along with Hepatitis in 18 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Hepatitis: INFLAMMATION of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 60-year-old male with cerebral infarction was admitted to our hospital and treated with edaravone." | 7.74 | A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient. ( Abe, M; Kaizu, K; Matsumoto, K, 2007) |
| "Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases." | 7.67 | Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. ( Beppu, T; Hanano, M; Idezuki, Y; Iga, T; Kawasaki, S; Sanjo, K; Sugiura, M; Sugiyama, Y, 1988) |
| "A 60-year-old male with cerebral infarction was admitted to our hospital and treated with edaravone." | 3.74 | A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient. ( Abe, M; Kaizu, K; Matsumoto, K, 2007) |
| "Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases." | 3.67 | Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. ( Beppu, T; Hanano, M; Idezuki, Y; Iga, T; Kawasaki, S; Sanjo, K; Sugiura, M; Sugiyama, Y, 1988) |
| "Patients with acute hepatitis and patients with compensated or decompensated cirrhosis of the liver have a decreased plasma clearance of hexobarbital." | 3.66 | [Drug metabolism in patients with liver disease (author's transl)]. ( Epping, J; Fuchshofen-Röckel, M; Heusler, H; Richter, E; Zilly, W, 1980) |
| "Antipyrine metabolism was normal or marginally impaired in patients with compensated cirrhosis or acute hepatitis, whereas it was frequently abnormal in those with chronic active hepatitis or advanced alcoholic liver disease." | 1.26 | Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. ( Cooksley, WG; Farrell, GC; Hart, P; Powell, LW, 1978) |
| "Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man." | 1.25 | Determinants of serum antipyrine half-lives in patients with liver disease. ( Branch, RA; Herbert, CM; Read, AE, 1973) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (88.89) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| TERZANI, A | 1 |
| Abe, M | 1 |
| Kaizu, K | 1 |
| Matsumoto, K | 1 |
| Sotaniemi, EA | 1 |
| Pelkonen, RO | 1 |
| Puukka, M | 1 |
| Okolicsànyi, L | 1 |
| Orlando, R | 1 |
| Lirussi, F | 1 |
| Naccarato, R | 1 |
| Dal Brun, G | 1 |
| Geller, LI | 1 |
| Griaznova, MV | 1 |
| Bulgakova, OS | 1 |
| Kozlova, ZP | 1 |
| Kuntz, HD | 1 |
| Meessen, D | 1 |
| May, B | 1 |
| Takashi, M | 1 |
| Musha, H | 1 |
| Tsuchiya, S | 1 |
| Gotoh, N | 1 |
| Takayasu, K | 1 |
| Suzuki, N | 1 |
| Kotoda, K | 1 |
| Okuda, K | 1 |
| Richter, E | 1 |
| Epping, J | 1 |
| Fuchshofen-Röckel, M | 1 |
| Heusler, H | 1 |
| Zilly, W | 1 |
| Fabbri, A | 1 |
| Bianchi, GP | 1 |
| Marchesini, G | 1 |
| Farrell, GC | 1 |
| Cooksley, WG | 1 |
| Hart, P | 1 |
| Powell, LW | 1 |
| Ohnhaus, EE | 1 |
| Münch, U | 1 |
| Meier, J | 1 |
| Kawasaki, S | 1 |
| Sugiyama, Y | 1 |
| Iga, T | 1 |
| Hanano, M | 1 |
| Beppu, T | 1 |
| Sugiura, M | 1 |
| Sanjo, K | 1 |
| Idezuki, Y | 1 |
| Kogan, AS | 1 |
| Nepomniashchikh, VA | 1 |
| Villeneuve, JP | 1 |
| Thibeault, MJ | 1 |
| Ampelas, M | 1 |
| Fortunet-Fouin, H | 1 |
| LaMarre, L | 1 |
| Côté, J | 1 |
| Pomier-Layrargues, G | 1 |
| Huet, PM | 1 |
| Kupcová, V | 1 |
| Holomán, J | 1 |
| Turecký, L | 1 |
| Ulicná, O | 1 |
| Brixová, E | 1 |
| Adjepon-Yamoah, KK | 1 |
| Nimmo, J | 1 |
| Prescott, LF | 1 |
| Ackermann, E | 1 |
| Renger, F | 1 |
| Dökert, B | 1 |
| Walther, M | 1 |
| Branch, RA | 1 |
| Herbert, CM | 1 |
| Read, AE | 1 |
1 trial available for antipyrine and Hepatitis
| Article | Year |
|---|---|
[Pharmaco-metabolic activity in chronic hepatopathies: influence of treatment with UDPG].
Topics: Adult; Aged; Antipyrine; Chronic Disease; Clinical Trials as Topic; Female; Hepatitis; Humans; Liver | 1980 |
17 other studies available for antipyrine and Hepatitis
| Article | Year |
|---|---|
[DAMAGE FROM THERAPY].
Topics: Adrenal Cortex Hormones; Anemia; Anemia, Aplastic; Anticoagulants; Antipyrine; Blood Group Incompati | 1963 |
A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient.
Topics: Acute Kidney Injury; Antipyrine; Cerebral Infarction; Disseminated Intravascular Coagulation; Edarav | 2007 |
Measurement of hepatic drug-metabolizing enxyme activity in man. Comparison of three different assays.
Topics: Adult; Aged; Antipyrine; Cytochrome P-450 Enzyme System; Enzyme Induction; Female; Glucaric Acid; He | 1980 |
[Pharmacometabolic capacity of the liver and the effect of pancreozymin in chronic hepatitis, chronic pancreatitis and diabetes mellitus].
Topics: Adult; Antipyrine; Biotransformation; Cholecystokinin; Chronic Disease; Diabetes Mellitus; Hepatitis | 1982 |
[Hepatic elimination of indocyanine green and antipyrine in patients with chronic liver disease].
Topics: Antipyrine; Chronic Disease; Hepatitis; Humans; Indocyanine Green; Liver Diseases; Liver Function Te | 1982 |
[Clinical significance of antipyrine metabolism in patients with various liver diseases (author's transl)].
Topics: Antipyrine; Half-Life; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases; Liver Function Tests | 1981 |
[Drug metabolism in patients with liver disease (author's transl)].
Topics: Acute Disease; Adult; Antipyrine; Biological Availability; Biotransformation; Cholestasis; Female; H | 1980 |
Antipyrine clearance and response to interferon therapy in chronic hepatitis.
Topics: Antipyrine; Antiviral Agents; Hepatitis; Humans; Interferons | 1997 |
Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.
Topics: Acute Disease; Antipyrine; Ascites; Biotransformation; Chemical and Drug Induced Liver Injury; Chole | 1978 |
[Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
Topics: Antipyrine; Fatty Liver; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases; Pindolol | 1976 |
Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
Topics: Adult; Aged; Antipyrine; Chronic Disease; Female; Galactose; Galactosemias; Hepatitis; Humans; Indoc | 1988 |
[Effect of inflammation and cholestasis on the metabolic function of the liver].
Topics: Antipyrine; Biliary Tract Diseases; Hepatitis; Humans; Inactivation, Metabolic; Inflammation; Liver; | 1987 |
Drug disposition in patients with HBsAg-positive chronic liver disease.
Topics: Adult; Aminopyrine; Antipyrine; Female; Hepatitis; Hepatitis B Surface Antigens; Hepatitis, Chronic; | 1987 |
[Changes in metabolic function of the liver in patients with chronic hepatic diseases].
Topics: Antipyrine; Chronic Disease; Half-Life; Hepatitis; Humans; Liver; Liver Cirrhosis | 1985 |
Gross impairment of hepatic drug metabolism in a patient with chronic liver disease.
Topics: Adult; Antipyrine; Biotransformation; Chronic Disease; Female; Half-Life; Hepatitis; Humans; Jaundic | 1974 |
[Aminophenazone half life in patients with chronic liver parenchyma disorders].
Topics: Aminopyrine; Animals; Antipyrine; Chronic Disease; Fatty Liver; Female; Half-Life; Hepatitis; Humans | 1972 |
Determinants of serum antipyrine half-lives in patients with liver disease.
Topics: Adult; Alkaline Phosphatase; Antipyrine; Aspartate Aminotransferases; Bilirubin; Half-Life; Hepatiti | 1973 |